Protara Therapeutics is rated a Buy with a risk-adjusted fair value of $9.96 per share, compared to its current price around $4. The company focuses on a unique "pipeline-in-a-product" approach, developing TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations, both orphan drug indications with significant growth potential despite competition. Additionally, its IV Choline Chloride treatment targets severe choline deficiency in parenteral nutrition patients, with pivotal data expected in 2026 that could drive substantial revenue. Protara's strong cash position supports operations through 2028, reducing dilution risk and maintaining an attractive risk/reward profile despite clinical and competitive challenges.
US and Japanese officials are considering expanding the Federal Reserve's FIMA Repo Facility to help strengthen the yen by allowing Japan to exchange US Treasury holdings for dollars to buy yen. This move would involve the Fed printing new dollars, e...
West Fraser Timber reported flat adjusted EBITDA in Q2 2026, with a sharp year-over-year decline driven by weakness in North American engineered wood products. The company's cash flow is insufficient to cover capital expenditures and dividends withou...
Hexcel Corporation reported an 8% increase in Q2 sales and a 280 basis point rise in adjusted operating margin to 13.9%, driven by strong commercial aerospace demand from Airbus A350 and Boeing 787 programs. The company raised its 2026 sales and EPS ...
Restaurant Brands International (QSR) has been upgraded to a buy rating due to Burger King's successful turnaround, which has driven market share gains over McDonald's. Burger King posted an 8.5% comparable sales growth aided by the effective 'Reclai...
Bitcoin fell to around $63,900 after crude oil prices jumped nearly 5% due to Iran rejecting direct U.S. talks and setting conditions for reopening the Strait of Hormuz. This geopolitical tension pushed investors toward safer assets like the U.S. dol...
